ASX Announcements

Final Director's Interest Notice
Ceasing to be a substantial holder
2018 Year-end Business Update
Larry Glass to retire as a director and continue as CSO
Presentation at AusBiotech Invest and Partnering 2018
Appendix 4C - quarterly
Trofinetide ex-North America exclusive negotiation period
Neuren and ACADIA hold Rett syndrome SAB meeting
Change of Director's Interest Notice
FDA reaffirms positive benefit-risk of ACADIA's NUPLAZID